Mabwell's Adalimumab Biosimilar Hits Milestone in Indonesia
Mabwell, an innovation-driven biopharmaceutical company, has achieved a significant accomplishment by securing marketing authorization for its Adalimumab Injection 9MW0113, marketed as JUNMAIKANG in China, from the Indonesian Food and Drug Authority (BPOM). This approval marks a pivotal moment in the company's journey, emphasizing its growing role in the global pharmaceutical landscape.
A Trailblazer in Biosimilars
Mabwell has co-developed 9MW0113 alongside Junshi Biosciences, making it the first Adalimumab biosimilar from China to receive such recognition overseas. This approval is a testament to the rigorous development processes and the commitment of Mabwell to supply high-quality biologics to the market.
Global Expansion Strategy
With this achievement, Mabwell is advancing its strategy for international expansion. The company has entered into formal cooperation agreements for 9MW0113 in over ten countries, further solidifying its presence on the global stage. Additionally, Mabwell has submitted registration applications in various countries, which reflects its proactive approach to global healthcare challenges.
Commitment to Healthcare in Southeast Asia
Mr. Hu Huiguo, Board Director and Senior Vice President at Mabwell, highlighted Indonesia's potential, stating that it is the most populous country in Southeast Asia with increasing healthcare demands. As a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), Indonesia ensures a meticulous quality review process for pharmaceuticals, beneficial to both companies and patients alike.
About Mabwell
Founded with a vision to enhance healthcare, Mabwell is focused on developing innovative therapies, particularly in oncology and aging-related diseases. Their mission, “Explore Life, Benefit Health,” drives them to create impactful solutions that address critical medical needs globally.
Innovative Solutions for Global Health
Mabwell continues to explore new opportunities in the biopharmaceutical realm, aiming for more effective and accessible therapies. Their commitment is reflected in their ongoing research efforts and partnerships aimed at tackling various health challenges across the globe.
Frequently Asked Questions
What is Mabwell's major recent achievement?
Mabwell received marketing authorization for its Adalimumab biosimilar in Indonesia, marking a significant milestone in its expansion strategy.
What is 9MW0113?
9MW0113 is an Adalimumab biosimilar developed by Mabwell and Junshi Biosciences, designed to offer affordable and effective treatment options.
Why is this approval significant?
It signifies Mabwell’s commitment to enhancing healthcare access in populous regions and reinforces its position in the competitive biopharmaceutical market.
Where else has Mabwell's biosimilar been approved?
Mabwell has already secured approvals in more than ten countries and has submitted applications in additional regions, showcasing their global reach.
What is Mabwell's mission?
Mabwell's mission is centered around exploring life and benefiting health, focusing on offering innovative treatments, particularly in oncology and age-related diseases.
